Effect and mechanism of berberine against polycystic ovary syndrome

For women of reproductive age, polycystic ovary syndrome (PCOS) is not a rare heterogeneous endocrine disorder and metabolic dysfunction. Menstrual problems, hyperandrogenism, polycystic ovary (PCO) and infertility often affect these women, and they are also prone to metabolic syndrome (MS) and insulin resistance (IR). As an isoquinoline alkaloid, Berberine (BBR) is the main effective component of Coptis. BBR, as a multi-target, multipath plant extract, can interfere with the development of PCOS and relate to pathological process from many aspects, with less adverse reactions. It is mentioned in this review that BBR can alleviate IR, reduce the level of serum androgen, regulate lipid metabolism and moderate chronic inflammation. BBR is often used in combination with metformin, compound cyproterone (CPA) and other drugs, in order to achieve better therapeutic effect on PCOS.

Automated summary

PCOS is a common disorder in women of reproductive age, affecting their physiology and metabolism, and often leading to metabolic syndrome and insulin resistance; Berberine can intervene in the development of PCOS in multiple ways, including alleviating insulin resistance, reducing androgen levels, regulating lipid metabolism, and reducing inflammation.